CN112569159A - 一种防脱护发组合物、护发精华液及其制备方法 - Google Patents
一种防脱护发组合物、护发精华液及其制备方法 Download PDFInfo
- Publication number
- CN112569159A CN112569159A CN202110011622.4A CN202110011622A CN112569159A CN 112569159 A CN112569159 A CN 112569159A CN 202110011622 A CN202110011622 A CN 202110011622A CN 112569159 A CN112569159 A CN 112569159A
- Authority
- CN
- China
- Prior art keywords
- hair
- parts
- hair loss
- leaf extract
- essence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 89
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 68
- 230000003676 hair loss Effects 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 208000024963 hair loss Diseases 0.000 title claims abstract description 43
- 230000003405 preventing effect Effects 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000000284 extract Substances 0.000 claims abstract description 25
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 20
- 235000009008 Eriobotrya japonica Nutrition 0.000 claims abstract description 13
- 240000000783 Origanum majorana Species 0.000 claims abstract description 11
- 235000006297 Origanum majorana Nutrition 0.000 claims abstract description 11
- 108010084695 Pea Proteins Proteins 0.000 claims abstract description 11
- 235000019702 pea protein Nutrition 0.000 claims abstract description 11
- 239000011616 biotin Substances 0.000 claims abstract description 10
- 229960002685 biotin Drugs 0.000 claims abstract description 10
- 235000020958 biotin Nutrition 0.000 claims abstract description 10
- 230000003658 preventing hair loss Effects 0.000 claims description 13
- 241001092070 Eriobotrya Species 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 9
- 239000002562 thickening agent Substances 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical class CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- -1 antiseptic Substances 0.000 claims description 4
- 230000003750 conditioning effect Effects 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Chemical class C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 2
- 241000195940 Bryophyta Species 0.000 claims description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 2
- 239000004386 Erythritol Chemical class 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Chemical class OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical class C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 229960003237 betaine Drugs 0.000 claims description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical class OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 229940113120 dipropylene glycol Drugs 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical class OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 claims description 2
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 2
- 229940101267 panthenol Drugs 0.000 claims description 2
- 235000020957 pantothenol Nutrition 0.000 claims description 2
- 239000011619 pantothenol Substances 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 2
- 229940104256 sodium taurate Drugs 0.000 claims description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical class [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 229940104261 taurate Drugs 0.000 claims description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical class NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Chemical class NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims 1
- 229960000458 allantoin Drugs 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 229960004025 sodium salicylate Drugs 0.000 claims 1
- 230000003656 anti-hair-loss Effects 0.000 abstract description 19
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 244000061508 Eriobotrya japonica Species 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 210000003780 hair follicle Anatomy 0.000 description 39
- 239000000686 essence Substances 0.000 description 23
- 231100000360 alopecia Toxicity 0.000 description 18
- 210000000130 stem cell Anatomy 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 210000004761 scalp Anatomy 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 230000003779 hair growth Effects 0.000 description 7
- 239000003098 androgen Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000000442 hair follicle cell Anatomy 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000031774 hair cycle Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 4
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 201000002996 androgenic alopecia Diseases 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- RRJOMESUBQAYOA-BZSNNMDCSA-N (2S)-2-[[(2S)-2-[[2-[[(2S)-2-acetamido-6-aminohexanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-6-aminohexanamide Chemical compound NCCCC[C@H](NC(=O)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)CC1=CN=CN1 RRJOMESUBQAYOA-BZSNNMDCSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 206010068168 androgenetic alopecia Diseases 0.000 description 3
- 229960003473 androstanolone Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- FRWNAQDBODEVAL-VMPITWQZSA-N (5e)-5-[(4-nitrophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical group C1=CC([N+](=O)[O-])=CC=C1\C=C\1C(=O)NC(=S)S/1 FRWNAQDBODEVAL-VMPITWQZSA-N 0.000 description 2
- QNMKGMUGYVWVFQ-UHFFFAOYSA-N 2alpha-Hydroxyursolic acid Natural products CC12CC(O)C(O)C(C)(C)C1CCC1(C)C2CC=C2C3C(C)C(C)(C)CCC3(C(O)=O)CCC21C QNMKGMUGYVWVFQ-UHFFFAOYSA-N 0.000 description 2
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 2
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 2
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000003273 male-pattern hair loss Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229940094944 saccharide isomerate Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种防脱护发组合物,涉及防脱护发技术领域。所述防脱护发组合物,包含以下重量份的组分:枇杷叶提取物1‑5份、生物素三肽‑1 1‑10份、乙酰基四肽‑3 1‑10份、水解豌豆蛋白1‑5份和墨角兰叶提取物1‑5份。本发明提供的防脱护发组合物能够从脱发根源解决脱发难题,且对身体没有副作用的,来源均为绿色天然组分。
Description
技术领域
本发明涉及防脱护发技术领域,尤其是一种防脱护发组合物、护发精华液及其制备方法。
背景技术
随着社会压力不断增大和生活节奏的加快,环境的不断恶化,以及不良饮食的饮食习惯,我国的脱发患者越来越多,且有向低龄发展的趋势。如今随着社会的进步,人们对自身仪表仪容更为重视,因此,作为个人护理用品领域,防脱发产品的研究与开发愈来愈受到世界医药与化妆品界的重视。
正常成年人约有15万根头发。头发从头皮的毛囊深部的毛球不断向外生长,此周期可持续5~7年。该周期被称为头发的生长周期。头发生长周期的平衡被打乱后会妨碍头发的生长,导致头发稀疏、脱落。头发生长周期的紊乱所导致的脱发,是由于生长周期缩短,头发还未完全生长便提前进入退化期,休止期所造成的。另外与男性雄性激素的分泌,头发相关细胞机能的低下,血液循环障碍所导致的营养不良也有着密切的关系。脱发按病因又可分为雄性激素源性脱发、脂溢性脱发又称脂秃、斑秃等十几种。
雄性激素源性脱发的发病机制主要是头部毛发严格地受雄性激素的影响,男性激素的睾丸酮,在毛囊处经5α-还原酶催化变成活性更高的5,2-二氢睾丸酮(DHT),这种变化是不可逆的,而DHT是引起脱发的主要原因,因此抑制5α-还原酶活性,才能从根源处解决雄性激素源性脱发。脂溢性脱发在发生过程中表现头皮脂分泌增强,头部油脂多并伴有明显脱发。目前,比较公认的发病机理与雄激素、雄激素受体及雄激素代谢相关酶密切相关。另外头皮紧张造成的局部血液循环障碍,引起毛囊、毛乳头的末梢毛细血管的流量减少,毛乳头和毛母细胞的养料物质供应不足,使头发的生长出现异常。头皮的微炎症也会影响毛囊的头发再生。角质形成细胞对外界的刺激,污染、紫外线照射均有应答,释放IL-1α、IL-1β及其他白细胞介素,这些细胞因子已证实对体外培养的毛囊生长有抑制作用。抑制白细胞介素将会改善微炎症现象,帮助毛囊正常生长。
目前市场上出现了许多宣称针对病理性脱发的产品。主要可以分为两大类,一种是以中医理论为基础,复配了多种中药提取物,主要的功效是杀菌,滋养和控油,根据消费者的反馈来看防脱效果不是很理想。另一种是添加了西药西地那非、米诺地尔等活性成分,长期使用会引起多种不良反应和副作用,对身体造成危害。
发明内容
基于此,本发明的目的在于克服上述现有技术的不足之处而提供一种能够从脱发根源解决脱发难题,且对身体没有副作用的,来源绿色天然的防脱护发组合物。
为实现上述目的,本发明所采取的技术方案为:一种防脱护发组合物,包含以下重量份的组分:枇杷叶提取物1-5份、生物素三肽-1 1-10份、乙酰基四肽-3 1-10份、水解豌豆蛋白1-5份和墨角兰叶提取物1-5份。
本发明通过枇杷叶提取物、生物素三肽-1、乙酰基四肽-3、水解豌豆蛋白1-5份和墨角兰叶提取物的配合使用,提供了一种从抑制5α-还原酶,促进毛囊细胞的增殖,改善头皮血管微循环,抑制头皮炎症等多个方面解决脱发问题的防脱护发组合物。
枇杷叶提取物与头发生长周期中的成长期关系密切相关,其作用于头发生长周期中成长期的毛囊细胞,促进毛母细胞持续分裂增殖,最终达到促进头发生长的目的。VEGF和血管的再生有着密切的联系,血管的再生可以改善和促进毛根附近的血液流通,改善营养供应不足,促进毛发生长。FGF-5会导致头发提前进入退化期,因此抑制FGF-5的产生可以预防及改善脱发。研究表明枇杷叶提取物具有促进FGF-7,VEGF mRNA和FGF-5mRNA的生成,促进毛乳头细胞增殖和抑制睾丸素5α-还原酶活性的作用,因此是良好的生发原料。枇杷叶提取物中的主要活性成分是科罗索酸,已有研究表明科罗索酸具有良好生发效果。
毛囊的大小是由毛乳头和细胞外基质的大小决定的。健康的毛乳头会产生细胞外基质蛋白如胶原蛋白III和固定纤维如层粘连蛋白、胶原蛋白VII,使发根结实。如果细胞外基质更新出了问题,头发会变得脆弱。这样循环下去,毛囊会最终萎缩。乙酰基四肽-3通过成纤维细胞,加速细胞外基质蛋白的合成,如层粘连蛋白,胶原蛋白III和VII;直接作用于毛囊周围组织,增大毛囊的体积和长度;修复表皮-真皮连接组织(DEJ),促进头发固定在毛囊内。
研究发现生物素三肽-1具有三肽-1的作用,能增加细胞外基质如胶原蛋白IV和层粘连蛋白5合成,延缓毛囊衰老,减少二氢睾丸激素(DHT)的产生来改善毛囊的结构,有利头发固着在真皮毛囊内,防止脱发;激活组织修复基因表达,有利于头皮结构重建和修复;促进纤维细胞增殖和分化,刺激头发生长。
在脱发人群中,有大约70%属于脂溢性脱发(雄激素源性脱发),即由于体内的睾酮经5a-还原酶作用,生成二氢睾酮(DHT),毛囊细胞对DHT极为敏感,过高的DHT会刺激细胞产生各种细胞因子(如TGF-β2),引起毛囊细胞的退化、早衰、萎缩,从而降低发根的养分供应,最终毛发脱落。水解豌豆蛋白可降低人毛囊毛乳头细胞中TGF-β1生产量,降低脱发信号转导,并且能够增加毛乳头中纤维细胞的增殖。
毛囊中含有毛囊干细胞,毛囊上皮细胞中的毛囊干细胞是一类存在于所有能自我更新组织中的原始祖细胞,它在细胞生长和分化中起主导作用。毛乳头上移是毛囊干细胞激活的关键因素。研究表明1%的水解豌豆蛋白就能增加干细胞分化有关细胞因子(VEGF,TGF-β1,IL-6)表达,促进毛囊干细胞的增殖,促进毛囊生长。
17型胶原蛋白是一种使表皮结合、附着于基底膜上的蛋白质,在毛囊中存在于隆起区域的毛囊干细胞中。这些毛囊干细胞产生出作为毛发的“起源”的毛母细胞,并将其供应到毛囊伸出的毛乳头处。在毛乳头处,毛母细胞反复分裂,成长为毛发,使得毛发循环得以进行。如果17型胶原蛋白被分解,毛囊干细胞就无法维持干细胞的功能(即处于未分化的状态),分化成为角质化细胞,变成头皮屑或污垢脱落。也就是说,该毛囊中无法再形成新的毛发,毛囊会逐渐缩小,最终使毛囊本身消失。“17型胶原蛋白”存在于毛囊干细胞中,是维持毛囊干细胞所必须的。“17型胶原蛋白”的分解会导致“发量减少的过程”的开始,最终使得毛囊本身消失。“17型胶原蛋白”的存在,能有效阻止该过程。墨角兰萃取精华具有促进17型胶原蛋白1αmRNA表达的作用,促进了17型胶原蛋白的生成,并且能够抑制睾酮5α-还原酶活性的作用。众所周知,衰老或产后等使得雌性激素减少,会导致作为生发促进因子之一的BMP-2表达水平低下,墨角兰萃取精华能够促进BMP-2mRNA表达的作用。
优选地,所述的防脱护发组合物,包含以下重量份的组分:枇杷叶提取物1-2份、生物素三肽-1 1-5份、乙酰基四肽-3 1-5份、水解豌豆蛋白1-3份和墨角兰叶提取物1-3份。
进一步优选地,所述的防脱护发组合物,包含以下重量份的组分:枇杷叶提取物1份、生物素三肽-1 2.5份、乙酰基四肽-3 5份、水解豌豆蛋白1份和墨角兰叶提取物2份。
通过大量创造性试验,得到了防脱护发组合物的最优化的配方。
同时,本发明提供了所述的防脱护发组合物在护发素、焗油膏、洗发水、护发精华液、护发摩丝或美发定型产品中的应用。
此外,本发明还提供了一种包含所述防脱护发组合物护发精华液。
优选地,所述的护发精华液,还包含以下重量份的组分:保湿剂1-10份、防腐剂0.05-1份、增稠剂0.1-0.5份和水。
优选地,所述的护发精华液,如下(a)-(c)中的至少一种:
(a)所述保湿剂为透明质酸钠、甘油、丙二醇、1,3-丁二醇、双丙甘醇、甜菜碱、赤藓醇、糖类同分异构体、海藻糖、泛醇中的至少一种;
(b)所述防腐剂为辛酰羟肟酸、苯甲酸钠、尼泊金酯类、苯甲醇、苯氧乙醇、多元醇中的至少一种;
(c)所述增稠剂为卡波姆、纤维素、黄原胶、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、丙烯酰二甲基牛磺酸铵/VP共聚物中的至少一种。
同时,本发明还提供了所述护发精华液的制备方法,包括如下步骤:
(1)将保湿剂、防腐剂、增稠剂和水,依次加入水相锅,搅拌均匀,升温至80-85℃后,均质3-5min,分散均匀,得到混合物;
(2)将步骤(1)中得到的混合物搅拌降温至40-45℃,将防脱护发组合物加入水相锅,搅拌5-10min,分散均匀,即得到所述的护发精华液。
相对于现有技术,本发明的有益效果为:(1)本发明提供的防脱护发组合物能够从脱发根源解决脱发难题,且对身体没有副作用的,来源均为绿色天然组分;(2)本发明提供的防脱护发组合物从抑制5α-还原酶,促进毛囊细胞的增殖,改善头皮血管微循环,抑制头皮炎症等多个方面解决脱发问题。
具体实施方式
为更好的说明本发明的目的、技术方案和优点,下面将结合具体实施例对本发明作进一步说明。
本申请设置实施例1-5,具体实施例1-5所述护发精华液的组分和重量份选择如表1、表2和表3所示,其中,护发精华液的总的重量份为100份:
表1防脱护发组合物的重量份选择
防脱护发组合物 | 实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 |
枇杷叶提取物 | 1 | 5 | 1 | 2 | 1 |
生物素三肽-1 | 10 | 1 | 5 | 1 | 2.5 |
乙酰基四肽-3 | 1 | 10 | 1 | 5 | 5 |
水解豌豆蛋白 | 5 | 1 | 1 | 3 | 1 |
墨角兰叶提取物 | 1 | 5 | 3 | 1 | 2 |
表2护发精华液的其余组分选择
表3护发精华液的其余组分的重量份选择
实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | |
保湿剂 | 1 | 10 | 5 | 5 | 5 |
防腐剂 | 0.05 | 1 | 0.5 | 0.5 | 0.5 |
增稠剂 | 0.1 | 0.5 | 0.3 | 0.3 | 0.3 |
水 | 余量 | 余量 | 余量 | 余量 | 余量 |
按照表1、表2和表3进行称量后,实施例所述护发精华液的制备方法,包括如下步骤:
(1)将保湿剂、防腐剂、增稠剂和水,依次加入水相锅,搅拌均匀,升温至80-85℃后,均质3-5min,分散均匀,得到混合物;
(2)将步骤(1)中得到的混合物搅拌降温至40-45℃,将防脱护发组合物加入水相锅搅拌5-10min,分散均匀,即得到所述的护发精华液。
同时,本申请设置对比例1-10,对比例1-9的防脱护发组合物的重量份选择如表4所示,对比例的其余组分和重量份的选择以及制备方法与实施例5完全相同,对比例10为市面上常见的护发精华液——柳屋生发营养液。
表4对比例的防脱护发组合物的重量份选择
试验例1
为了验证本发明中公开的防脱发组合物的功效,实施例1-5和对比例1-9的防脱发组合物的防脱效果,按照上述所述的方法制成防脱护发精华液,包含有实施例1-5的防脱发组合物的防脱发精华液,包含对比例1-9的组合物的防脱发精华液,对比例10为市面上常见的护发精华液。
1.有效毛囊密度和防脱发情况检测
1.1试验设置:
设置15组试验组,分别编号为1-15,每组20名测试人员(包括10名男性,10名女性),年龄在25-55岁之间,其中,每组选择的20名测试人员的男性的脱发等级为II-IV型,女性的脱发等级为I型或II型。
男性脱发等级可分为7种类型,分别是:I型:正常或基本正常发型:II型:额颞部发际线呈三角形后移,距两耳道连接的冠状线可达2厘米;III型:两颞角退缩超越过冠状线前2厘米,顶部显稀疏;IV型:两颞及发际明显退缩,伴额中部发际后退,但期间有密度中等的毛发带相隔:V型:额颞和顶部裸露区扩大,期间毛发带狭窄而稀疏VI型:马蹄形脱发,侧面和后面脱发区增加;VII型:严重形式,除马蹄形脱发外,耳周和枕部有脱发。
女性脱发等级分类可分为3种类型,分别是:I型(轻度):冠状区前面头发变薄,须改变发型来掩饰,前额发际线完整;第二部临床实验研究雄激素源性脱发中医辨证分型与毛发电镜实验观察的分析;II型(中度):冠状区前面头发变薄更明显,脱发区范围扩大,改变发型已很难掩饰;III型(重度):顶部已完全脱发或裸露,但前额发际线仍完整。
1.2使用方法:
编号1-15的试验组,成员每天早、晚各使用一次防脱发精华液,每次取3mL防脱发精华液,将精华液涂抹至脱发处头皮,并按摩5-10min;测试期间,所有测试人员除使用测试用的防脱发精华液外,不使用其他防脱发的产品。
1.3有效毛囊密度检测结果:
在测试人员头部脱发处,选取面积为3cm x 3cm的检测区域,采用毛囊毛发分析仪分别拍摄测试人员在第0周、4周、8周时的检测区域,结果见表5所示:
表5头发毛囊密度
由表5可知,实施例1-5制备的防脱发精华液应用8周后,采用毛囊毛发分析仪测试后,脱发效果有明显的改善,使用实施例后的试验组成员的头发毛囊密度均达到了100以上。对比例1-5为防脱护发组合物缺少某一种组分,使用后的试验组成员的头发毛囊密度为80%左右,相比于实施例,下降明显;对比例6-8为缺少其中某两种或3种组分时,防脱护发的效果急剧下降。因此,本发明提供的防脱护发组合物各组分间具有相互相同的作用。
1.4止脱发效果
收集测试人员梳发时的头发脱落根数,收集使用防脱发精华液后第0周与第10周是测试人员的脱发脱落数,每次收集的方法具体为:在铺开的1米见方的双层纱布上梳发,收集并计算纱布上附着的头发,取20名测试人员的平均脱发脱落数,结果见表6所示:
表6梳发脱落数
由表6可知,实施例1-5制备的防脱发精华液应用10周后,梳发脱落数明显减少,脱发效果有明显的改善。对比例1-5为防脱护发组合物缺少某一种组分,使用后的试验组成员的梳发脱落数有所提升,相比于实施例,提升明显;对比例6-8为缺少其中某两种或3种组分时,防脱护发的效果急剧下降。对比例10为柳屋生发液,使用10周后,梳发脱落数仍有12根,效果并不显著,且明显差于本实施例提供的护发精华液。因此,本发明提供的防脱护发组合物各组分间具有相互相同的作用。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和范围。
Claims (8)
1.一种防脱护发组合物,其特征在于,包含以下重量份的组分:枇杷叶提取物1-5份、生物素三肽-1 1-10份、乙酰基四肽-3 1-10份、水解豌豆蛋白1-5份和墨角兰叶提取物1-5份。
2.如权利要求1所述的防脱护发组合物,其特征在于,包含以下重量份的组分:枇杷叶提取物1-2份、生物素三肽-1 1-5份、乙酰基四肽-3 1-5份、水解豌豆蛋白1-3份和墨角兰叶提取物1-3份。
3.如权利要求2所述的防脱护发组合物,其特征在于,包含以下重量份的组分:枇杷叶提取物1份、生物素三肽-1 2.5份、乙酰基四肽-3 5份、水解豌豆蛋白1份和墨角兰叶提取物2份。
4.一种如权利要求1-3任一项所述的防脱护发组合物在护发素、焗油膏、洗发水、护发精华液、护发摩丝或美发定型产品中的应用。
5.一种护发精华液,其特征在于,包含权利要求1-3任一项所述的防脱护发组合物。
6.如权利要求5所述的护发精华液,其特征在于,还包含以下重量份的组分:保湿剂1-10份、防腐剂0.05-1份、增稠剂0.1-0.5份和水。
7.如权利要求6所述的护发精华液,其特征在于,如下(a)-(c)中的至少一种:
(a)所述保湿剂为透明质酸钠、甘油、丙二醇、1,3-丁二醇、双丙甘醇、尿囊素、甜菜碱、赤藓醇、糖类同分异构体、海藻糖、泛醇中的至少一种;
(b)所述防腐剂为辛酰羟肟酸、苯甲酸钠、尼泊金酯类、苯甲醇、苯氧乙醇、水杨酸钠、多元醇中的至少一种;
(c)所述增稠剂为卡波姆、纤维素、黄原胶、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、丙烯酰二甲基牛磺酸铵/VP共聚物中的至少一种。
8.一种如权利要求6或7所述的护发精华液的制备方法,其特征在于,包括如下步骤:
(1)将保湿剂、防腐剂、增稠剂和水,依次加入水相锅,搅拌均匀,升温至80-85℃后,均质3-5min,分散均匀,得到混合物;
(2)将步骤(1)中得到的混合物搅拌降温至40-45℃,将防脱护发组合物加入水相锅,搅拌5-10min,分散均匀,即得到所述的护发精华液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110011622.4A CN112569159A (zh) | 2021-01-04 | 2021-01-04 | 一种防脱护发组合物、护发精华液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110011622.4A CN112569159A (zh) | 2021-01-04 | 2021-01-04 | 一种防脱护发组合物、护发精华液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112569159A true CN112569159A (zh) | 2021-03-30 |
Family
ID=75144820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110011622.4A Pending CN112569159A (zh) | 2021-01-04 | 2021-01-04 | 一种防脱护发组合物、护发精华液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112569159A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115252519A (zh) * | 2022-08-03 | 2022-11-01 | 浙江熙正霖生物科技有限公司 | 一种具有生物活性成分的护发精华液及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105106028A (zh) * | 2015-08-28 | 2015-12-02 | 深圳市维琪医药研发有限公司 | 一种用于毛发生长的多肽组合物 |
CN108309896A (zh) * | 2018-04-29 | 2018-07-24 | 佛山云裳化妆品有限公司 | 一种护发防脱组合物及其应用 |
CN109846773A (zh) * | 2018-11-26 | 2019-06-07 | 广州瑞誉化工科技有限公司 | 一种可抑制脂溢性脱发的头皮用组合物及其制备方法和应用 |
CN111658580A (zh) * | 2020-06-23 | 2020-09-15 | 广西和桂集团有限公司 | 含有多种肽与植物提取物的生发和/或白发转黑发精华液及其制备方法 |
-
2021
- 2021-01-04 CN CN202110011622.4A patent/CN112569159A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105106028A (zh) * | 2015-08-28 | 2015-12-02 | 深圳市维琪医药研发有限公司 | 一种用于毛发生长的多肽组合物 |
CN108309896A (zh) * | 2018-04-29 | 2018-07-24 | 佛山云裳化妆品有限公司 | 一种护发防脱组合物及其应用 |
CN109846773A (zh) * | 2018-11-26 | 2019-06-07 | 广州瑞誉化工科技有限公司 | 一种可抑制脂溢性脱发的头皮用组合物及其制备方法和应用 |
CN111658580A (zh) * | 2020-06-23 | 2020-09-15 | 广西和桂集团有限公司 | 含有多种肽与植物提取物的生发和/或白发转黑发精华液及其制备方法 |
Non-Patent Citations (4)
Title |
---|
RINNA想要一个很长的名: "护发丰盈精华液", 《百度》 * |
佚名: ""Gebiotide®养发肽原液", 《百度》 * |
小龙: "迷迭香的功效与作用", 《百度》 * |
水母真探社: "惊呆!秃子也能长出新头发,日本高新黑科技,90天让你满头黑发!", 《百度》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115252519A (zh) * | 2022-08-03 | 2022-11-01 | 浙江熙正霖生物科技有限公司 | 一种具有生物活性成分的护发精华液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1899012B1 (de) | Mittel enthaltend l-carnitin oder l-carnitinderivate und mindestens eine bestimmte weitere substanz | |
KR100839704B1 (ko) | 발모 및 육모 조성물 | |
JP3108586B2 (ja) | 育毛剤 | |
CN110123659B (zh) | 一种防脱发组合物及其在制备防脱发洗护产品中的应用 | |
US20120220541A1 (en) | Use of yeast peptide hydrolysate as an active agent for strengthening hair | |
CN111803426A (zh) | 防脱固发营养液及制备方法 | |
WO2016046848A2 (en) | Novel formulation of concentrated natural actives in oil-water microemulsion for hair fall prevention and increase in hair density | |
CN113350219A (zh) | 一种防脱固发组合物及含其洗发露及该洗发露的制备方法 | |
CN108938445B (zh) | 一种防脱发组合物和应用以及包括其的防脱发产品和制备方法 | |
CN113712883A (zh) | 一种含铁皮石斛提取物的修护霜及其制备方法 | |
CN112569159A (zh) | 一种防脱护发组合物、护发精华液及其制备方法 | |
US8933036B2 (en) | Cosmetic and/or pharmaceutical composition comprising a yeast peptide hydrolysate and use of the yeast peptide hydrolysate as an active agent for strengthening hair | |
JP5259127B2 (ja) | ツツジ科エリカ属植物由来成分を少なくとも含む外皮系組織用組成物 | |
JP2001139436A (ja) | 養毛・育毛剤 | |
JP7161302B2 (ja) | Wnt10b産生促進剤、及びそれを含有する頭皮頭髪用化粧料 | |
JPH0725652B2 (ja) | 新規な頭皮向け美髪用組成物 | |
CN114929238B (zh) | 用于防止脱发和促进生发的组合物 | |
WO2012068714A1 (zh) | 毛发生长促进剂 | |
US20230023847A1 (en) | Composition for preventing hair loss and promoting hair regrowth | |
CN117959228B (zh) | 一种含天然植物成分的去屑防脱洗发水及其制备方法 | |
JP7236755B2 (ja) | 育毛用組成物、遺伝子の発現促進用組成物 | |
CN117338687A (zh) | 一种护发育发组合物及其制备方法和应用 | |
CN117503748A (zh) | 对甲氧基肉桂酸乙酯的生发、防脱用途 | |
CN112842932A (zh) | 一种促进睫毛生长的精华液及其制备方法 | |
WO2023222847A1 (en) | Olfactory receptor 2a4/7 agonist for promoting hair growth and improving aesthetic aspect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210330 |